Pacific Biosciences

PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.

The nanopore ZMW can enable lower starting amounts of DNA for PacBio sequencing, and may eventually enable direct RNA sequencing.  

The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.

PacBio has released new software, which has increased read lengths and throughput, and aims to launch a new sample prep protocol and chemistry this year.

Although PacBio's product and services revenues were up 17 percent, total revenues declined 3 percent due to a lack of contractual revenue in the quarter.

The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction. 

The firm is aiming to sell 15.4 million shares of common stock at $3.10 per share, and plans to use the proceeds for working capital and capital expenditures.

The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.

The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million. 

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.